CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Standard CareWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug448 Ivermectin plus Nitazoxanide Wiki 0.71
drug809 Systemic indirect endovenous ozone therapy Wiki 0.71
drug541 Natural Honey Wiki 0.71

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D007251 Influenza, Human NIH 0.27
D013577 Syndrome NIH 0.11
D018352 Coronavirus Infections NIH 0.08
D014777 Virus Diseases NIH 0.08
D045169 Severe Acute Respiratory Syndrome NIH 0.05

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials


1 The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial

The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has been discovered recently in December 2019 from wuhan city in China to spread in more than 40 countries allover the world. This disease has gain the attention of all nations after it has been stated as a pandemic by the World Health Organization (WHO) in March 12, 2020. Currently no treatment has been proved to be efficient in the treatment of infected patients by COVID-19. Natural honey has been demonstrated as potent antimicrobial in many research investigations and has been considered a good alternative for antiviral drugs for the treatment of some viral infections. The investigators aim to study the efficacy of natural honey in the treatment of COVID-19 patients in this randomized , multicenter, controlled trial, comparing honey in one arm to standard care in the other arm.

NCT04323345 COVID-19 Dietary Supplement: Natural Honey Other: Standard Care
MeSH:Coronavirus Infections

Primary Outcomes

Description: Percentage of patients turned from positive to negative swaps at day 14

Measure: Rate of recovery from positive to negative swaps

Time: 14 days

Description: Number of days till no fever

Measure: Fever to normal temperature in days

Time: 14 days

Description: Number of days till lungs recovery in chest X ray or CT

Measure: Resolution of lung inflammation in CT or X ray

Time: 30 days

Secondary Outcomes

Description: mortality rate in each group at 30 days

Measure: 30 days mortality rate

Time: 30 days

Description: Number of days from initiation of intervention till changing of the swap test result from positive to negative

Measure: Number of days till reaching negative swab results

Time: 30 days

2 Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope

Research Background and Rationale In December 2019, a new infectious respiratory disease emerged in Wuhan, Hubei province, China. An initial cluster of infections was linked to Huanan seafood market, potentially due to animal contact. Subsequently, human-to-human transmission occurred and the disease, now termed coronavirus disease 19 (COVID-19) rapidly spread within China and all over the world. A novel coronavirus, SARS-coronavirus 2 (SARS-CoV-2), which is closely related to SARS-CoV, was detected in patients and is believed to be the etiologic agent of the new lung disease. The causative agent of the current COVID-19 pandemic, SARS-CoV-2, is a single stranded positive sense RNA virus that is closely related to severe acute respiratory syndrome coronavirus (SARS-CoV).

NCT04360356 COVID-19 Combination Product: Ivermectin plus Nitazoxanide Other: Standard Care

Primary Outcomes

Description: COVID-19 PCR analysis

Measure: Number of Patients with COVID-19-negative PCR

Time: within 10 days

Secondary Outcomes

Description: improved breaths per minute for the patients

Measure: Number of patients with improved respiratory rate

Time: within 30 days

Description: Change in PaO2 in mmHg of the patients

Measure: Number of patients with improved PaO2

Time: within 30 days

Description: Serum IL6 in pg/mL of the patients

Measure: Number of patients with normalized Serum IL6

Time: within 30 days

Description: Serum TNFα in pg/mL of the patients

Measure: Number of patients with normalized Serum TNFα

Time: within 30 days

Description: Serum iron in microgram/dL of the patients

Measure: Number of patients with normalized Serum iron

Time: within 30 days

Description: Serum ferritinin microgram/L of the patients

Measure: Number of patients with normalized Serum ferritin

Time: within 30 days

Description: International normalized ratio "INR" for prothrombin time of 2

Measure: Number of patients with normalized International normalized ratio "INR" for prothrombin time

Time: within 30 days

Description: CBC for lymphocyte count in cells/microliter

Measure: Number of patients with normalized complete blood count "CBC"

Time: within 30 days

Description: Mortality rate [number of dead patients/total number of treated patients]

Measure: The Mortality rate among treated patients

Time: within 30 days


No related HPO nodes (Using clinical trials)